Latest News - Valeant

Wednesday, August 16, 2017 | Miscellaneous, Bausch+Lomb, Valeant

FDA: Inspection Issues at Bausch + Lomb Manufacturing Plant in Tampa Facility are Being Resolved

Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa. With this confirmation,…

Read the full story

Tuesday, August 08, 2017 | Valeant

FDA Rejects Valeant's Marketing Application for IOP Eye Drop Latanoprostene Bunod

In a complete response letter (CRL) to Valeant, the FDA did not approve the new drug application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%, citing Current Good Manufacturing Prac…

Read the full story

Tuesday, June 20, 2017 | Management/Leadership, Valeant

Valeant Investor John Paulson Appointed to Board

Valeant Pharmaceuticals announced Monday that John Paulson has been elected to serve as a director, bringing the total number of independent members on the company's board to 10. Mr. Paulson is pr…

Read the full story

Tuesday, June 06, 2017 | Acquisitions/Mergers, Bausch+Lomb, Carl Zeiss Meditec, Valeant

Report: Valeant in Talks to Sell Bausch + Lomb's Surgical Business to Carl Zeiss

Valeant is in in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec, according to a Bloomberg report, which cited people familiar with the matter. Valean…

Read the full story

Tuesday, May 09, 2017 | Clinical Trials, Bausch+Lomb, Valeant

Bausch + Lomb Announces PDUFA Date For Luminesse

Bausch + Lomb announced that the FDA accepted the new drug application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesse), and set a PDUFA action date of December 27, 2017. Lumines…

Read the full story

Thursday, March 30, 2017 | Management/Leadership, Bausch+Lomb, Valeant

Bausch + Lomb Announces US Management Team Leadership

Bausch + Lomb announced several changes to its management team designed to improve operational efficiencies. Joseph “Joe” Gordon, senior vice president and general manager, US Consumer …

Read the full story

Thursday, March 30, 2017 | Earnings & Financials, Valeant

Ackman: Investment in Valeant a 'Huge Mistake'

In his annual letter to investors of his hedge fund, Bill Ackman “deeply and profoundly” apologized for his investment in Valeant, a move that ultimately cost Pershing Square Capital Manag…

Read the full story

Tuesday, March 28, 2017 | Corporate Lawsuits, Valeant

Former Valeant CEO Michael Pearson Sues Company Over Unpaid Share Award

Former Valeant Pharmaceuticals CEO Michael Pearson filed a lawsuit in the US claiming that the company failed to deliver 3 million shares promised to him as part of an exit package. According to the c…

Read the full story

Tuesday, March 14, 2017 | Earnings & Financials, Valeant

Ackman Unloads Entire Stake in Valeant

After a long relationship that has seen the rapid rise and massive fall of Valeant’s stock price, Pershing Square Capital Management CEO Bill Ackman stated that his hedge fund has sold all its s…

Read the full story

Tuesday, February 21, 2017 | Acquisitions/Mergers, Eyegate Pharmaceuticals, Valeant

Valeant and Eyegate Enter into Licensing Agreement for EyeGate II Delivery System and EGP-437 Combination Product

Valeant Pharmaceuticals International and EyeGate Pharmaceuticals announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Va…

Read the full story

Thursday, December 01, 2016 | Acquisitions/Mergers, Valeant

Valeant Drops After Report Salix Sale Discussions Broke Down

Valeant Pharmaceuticals International Inc. dropped after a report that discussions to sell its gastrointestinal drugs unit to Japan’s Takeda Pharmaceutical Co. for about $10 billion have fallen …

Read the full story

Thursday, November 17, 2016 | Miscellaneous, Valeant

Ex-Valeant Executive, Ex-Pharmacy CEO Charged for Fraud Scheme

US prosecutors on Thursday filed charges against a former Valeant Pharmaceuticals International executive and a former CEO of mail order pharmacy Philidor Rx Services, alleging they engaged in a multi…

Read the full story

Wednesday, November 09, 2016 | Miscellaneous, Bausch+Lomb, Nicox , Valeant

Nicox Provides Update on Latanoprostene Bunod and AC-170

Nicox SA provided an update on the regulatory status of its key projects, latanoprostene bunod and AC-170. Valeant Pharmaceuticals has stated that Nicox's licensee for latanoprostene bunod, Bau…

Read the full story

Tuesday, November 08, 2016 | Earnings & Financials, Valeant

Valeant Shares Plunge as It Slashes Guidance Again

Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take long…

Read the full story

Tuesday, November 08, 2016 | Acquisitions/Mergers, Earnings & Financials, Bausch+Lomb, Paragon BioTeck , Valeant

Valeant Agrees to Sell Paragon to Settle U.S. Antitrust Charges

Valeant Pharmaceuticals, which owns eye care products maker Bausch & Lomb, has agreed to sell Paragon Holdings to settle allegations that its acquisition of the smaller company was illegal under a…

Read the full story
Load More